23andMe’s (ME) Sell (E+) Rating Reiterated at Weiss Ratings

23andMe (NASDAQ:ME)‘s stock had its “sell (e+)” rating reissued by Weiss Ratings in a research report issued to clients and investors on Saturday,Weiss Ratings reports.

23andMe Price Performance

Shares of 23andMe stock remained flat at $3.61 during trading hours on Friday. The company’s stock had a trading volume of 475,228 shares, compared to its average volume of 194,032. The company has a market capitalization of $94.29 million, a price-to-earnings ratio of -0.14 and a beta of 1.14. 23andMe has a one year low of $2.65 and a one year high of $16.52. The company’s 50-day moving average is $3.51 and its two-hundred day moving average is $5.65.

23andMe (NASDAQ:ME) last released its earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter. The business had revenue of $44.07 million for the quarter, compared to analysts’ expectations of $50.30 million. 23andMe had a negative return on equity of 129.98% and a negative net margin of 318.39%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in 23andMe by 0.7% during the third quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock valued at $1,476,000 after buying an additional 28,252 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of 23andMe during the 3rd quarter valued at $805,000. FMR LLC lifted its holdings in shares of 23andMe by 24.0% during the 3rd quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after acquiring an additional 192,099 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in 23andMe during the 2nd quarter worth $203,000. Finally, AQR Capital Management LLC increased its holdings in 23andMe by 145.8% in the 2nd quarter. AQR Capital Management LLC now owns 444,222 shares of the company’s stock valued at $174,000 after purchasing an additional 263,468 shares in the last quarter. Institutional investors and hedge funds own 36.10% of the company’s stock.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.